Part B: Supplementary Information Sheet (SIS) |
FR Recognition List Number
|
020
|
Date of Entry 09/09/2008
|
FR Recognition Number
|
7-136
|
Standard | |
CLSI I/LA2-A2 (Replaces I/LA2-A) Quality Assurance of Laboratory Tests for Autoantibodies to Nuclear Antigens: (1) Indirect Flurescence Assay for Microscopy and (2) Microtiter Enzyme Immunoassay Methods; Approved Guideline - Second Edition. |
|
Scope/AbstractThe elements of this guideline include: 1) a development plan for an effective analysis and evaluation; 2) a discussion of the planning and design considerations that are necessary for a successful evaluation; 3) a description of requirements for conducting the evaluation through monitoring and database management; and 4) a brief review of the analytical performance measures that must be in place before testing clinical specimens. |
|
Extent of Recognition
|
Public Law, CFR Citation(s) and Procode(s)*
Regulation Number |
Device Name |
Device Class |
Product Code |
§866.5100 |
Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control
|
Class 2
|
DHN
|
§866.5100 |
Antinuclear Antibody (Enzyme-Labeled), Antigen, Controls
|
Class 2
|
LJM
|
§866.5100 |
Antinuclear Antibody, Antigen, Control
|
Class 2
|
LKJ
|
§866.5100 |
Extractable Antinuclear Antibody, Antigen And Control
|
Class 2
|
LLL
|
|
Relevant FDA Guidance and/or Supportive Publications*
Guidance for Industry and FDA Staff Recommendations for Anti-Nuclear Antibody (ANA) Test System Premarket (510(k)) Submissions, Issued January 2009.
Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices - Guidance for Industry and Food and Drug Administration Staff, issued September 2018. |
|
FDA Technical Contact
|
Standards Development Organization
|
FDA Specialty Task Group (STG)
|
*These are provided as examples and others may be applicable. |